Compugen Ltd. Announces Positive Therapeutic Effects of Relaxin Receptor Peptide Ligand in Pulmonary Fibrosis Animal Model

TEL-AVIV, Israel--(BUSINESS WIRE)--Compugen (NASDAQ:CGEN) announced today that CGEN-25009, a novel peptide that previously demonstrated the ability to activate the Relaxin receptor LGR7 (RXFP1) in cell based assays, has shown positive therapeutic effects in an animal model of pulmonary fibrosis. The Relaxin receptor is the third G-protein coupled receptor (GPCR) for which Compugen-discovered peptide ligands have shown therapeutic potential in disease models.
MORE ON THIS TOPIC